DE102004015099A1 - Imidazolderivate - Google Patents

Imidazolderivate Download PDF

Info

Publication number
DE102004015099A1
DE102004015099A1 DE102004015099A DE102004015099A DE102004015099A1 DE 102004015099 A1 DE102004015099 A1 DE 102004015099A1 DE 102004015099 A DE102004015099 A DE 102004015099A DE 102004015099 A DE102004015099 A DE 102004015099A DE 102004015099 A1 DE102004015099 A1 DE 102004015099A1
Authority
DE
Germany
Prior art keywords
imidazole derivatives
dollar
kinases
tumors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102004015099A
Other languages
English (en)
Inventor
Guenter Hoelzemann
Helene Crassier
Alfred Jonczyk
Wolfgang Staehle
Arne Sutter
Wilfried Rautenberg
Francesc Mitjans
Elisabet Rosell-Vives
Jaume Adan
Marta Soler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE102004015099A priority Critical patent/DE102004015099A1/de
Priority to KR1020067020089A priority patent/KR20060132965A/ko
Priority to AU2005231907A priority patent/AU2005231907A1/en
Priority to US10/593,295 priority patent/US20070225347A1/en
Priority to EP05716076A priority patent/EP1761503A2/de
Priority to JP2007505422A priority patent/JP2007530609A/ja
Priority to BRPI0508881-0A priority patent/BRPI0508881A/pt
Priority to PCT/EP2005/002746 priority patent/WO2005097755A2/de
Priority to CA002561585A priority patent/CA2561585A1/en
Priority to CNA200580010619XA priority patent/CN1938282A/zh
Priority to RU2006138150/04A priority patent/RU2006138150A/ru
Priority to ARP050101136A priority patent/AR048327A1/es
Publication of DE102004015099A1 publication Critical patent/DE102004015099A1/de
Priority to ZA200608998A priority patent/ZA200608998B/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Verbindungen der Formel I, DOLLAR F1 worin R·1·, R·2·, R·3·, R·4·, R·5·, R·6·, R·7·, R·8·, R·9·, R·10·, R·11·, X und X' die in Anspruch 1 angegebenen Bedeutungen haben, DOLLAR A sind Inhibitoren der Tyrosinkinasen, insbesondere TIE-2, und der Raf-Kinasen und können u. a. zur Behandlung von Tumoren eingesetzt werden.
DE102004015099A 2004-03-29 2004-03-29 Imidazolderivate Withdrawn DE102004015099A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE102004015099A DE102004015099A1 (de) 2004-03-29 2004-03-29 Imidazolderivate
PCT/EP2005/002746 WO2005097755A2 (de) 2004-03-29 2005-03-15 Imidazolderivate als hemmer von tyrosinkinase
CA002561585A CA2561585A1 (en) 2004-03-29 2005-03-15 Imidazol derivatives
US10/593,295 US20070225347A1 (en) 2004-03-29 2005-03-15 Imidazole Derivatives
EP05716076A EP1761503A2 (de) 2004-03-29 2005-03-15 Imidazolderivate als hemmer von tyrosinkinase
JP2007505422A JP2007530609A (ja) 2004-03-29 2005-03-15 イミダゾール誘導体
BRPI0508881-0A BRPI0508881A (pt) 2004-03-29 2005-03-15 derivados de imidazol
KR1020067020089A KR20060132965A (ko) 2004-03-29 2005-03-15 타이로신 키나아제 억제제로서의 이미다졸 유도체
AU2005231907A AU2005231907A1 (en) 2004-03-29 2005-03-15 Imidazol derivatives as tyrosine kinase inhibitors
CNA200580010619XA CN1938282A (zh) 2004-03-29 2005-03-15 作为酪氨酸激酶抑制剂的咪唑衍生物
RU2006138150/04A RU2006138150A (ru) 2004-03-29 2005-03-15 Производные имидазола
ARP050101136A AR048327A1 (es) 2004-03-29 2005-03-23 Derivados de imidazol
ZA200608998A ZA200608998B (en) 2004-03-29 2006-10-30 Imidazole derivatives as tyrosine kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004015099A DE102004015099A1 (de) 2004-03-29 2004-03-29 Imidazolderivate

Publications (1)

Publication Number Publication Date
DE102004015099A1 true DE102004015099A1 (de) 2005-10-20

Family

ID=34981611

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004015099A Withdrawn DE102004015099A1 (de) 2004-03-29 2004-03-29 Imidazolderivate

Country Status (13)

Country Link
US (1) US20070225347A1 (de)
EP (1) EP1761503A2 (de)
JP (1) JP2007530609A (de)
KR (1) KR20060132965A (de)
CN (1) CN1938282A (de)
AR (1) AR048327A1 (de)
AU (1) AU2005231907A1 (de)
BR (1) BRPI0508881A (de)
CA (1) CA2561585A1 (de)
DE (1) DE102004015099A1 (de)
RU (1) RU2006138150A (de)
WO (1) WO2005097755A2 (de)
ZA (1) ZA200608998B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076592A1 (en) * 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US20090124633A1 (en) * 2006-04-12 2009-05-14 Alfred Jonczyk N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
CN103910714A (zh) * 2013-01-09 2014-07-09 天津泰瑞倍药研科技有限公司 氟代环丁烷基咪唑类化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
EP1436265A4 (de) * 2001-09-27 2004-12-15 Smithkline Beecham Corp Chemische verbindungen

Also Published As

Publication number Publication date
ZA200608998B (en) 2008-07-30
EP1761503A2 (de) 2007-03-14
WO2005097755A2 (de) 2005-10-20
CN1938282A (zh) 2007-03-28
BRPI0508881A (pt) 2007-09-11
KR20060132965A (ko) 2006-12-22
RU2006138150A (ru) 2008-05-10
CA2561585A1 (en) 2005-10-20
JP2007530609A (ja) 2007-11-01
AU2005231907A1 (en) 2005-10-20
US20070225347A1 (en) 2007-09-27
AR048327A1 (es) 2006-04-19
WO2005097755A3 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
MX2007003470A (es) Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa.
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
CO6270257A2 (es) Derivados de piridazinona
AU2005293821A1 (en) N,N'-dithenylurea derivatives used in the form of kinase inhibitors
ATE451363T1 (de) 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
EA201000558A1 (ru) Производные имидазола
DE602004021838D1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
ATE554087T1 (de) Neue kinaseinhibitoren
DE602005009318D1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
TW200621751A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
ATE353888T1 (de) Chinazolinderivate
ECSP055537A (es) Monoclorhidrato de 2,5-diona-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirrol cristalino
DE502005007105D1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
WO2006125555A3 (de) Chinazolinone
BRPI0416690A (pt) derivados de pirrol
NO20042926L (no) Indolinonderivater nyttige sorn proteinkinaseinhibitorer
DE10334663A1 (de) Harnstoffderivate
WO2004092144A3 (en) Quinazoline compounds useful as p38 kinase inhibitors

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee